Is AJCC 8th Edition useful in qualifying melanoma patients to adjuvant therapy? | Zendy

Jacek Mackiewicz | Zendy; Andrzej Maćkiewicz | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Is AJCC 8th Edition useful in qualifying melanoma patients to adjuvant therapy?

Author(s) -

Jacek Mackiewicz,

Andrzej Maćkiewicz

Publication year - 2020

Publication title -

annals of translational medicine

Language(s) - English

Resource type - Journals

eISSN - 2305-5847

pISSN - 2305-5839

DOI - 10.21037/atm.2020.03.83

Subject(s) - medicine , melanoma , adjuvant , adjuvant therapy , oncology , dermatology , cancer , cancer research

Department of Medical and Experimental Oncology, Heliodor Święcicki Clinical Hospital, Poznan, Poland; Department of Biology and Environmental Studies, Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Center, Chair of Medical Biotechnology, Poznan University of Medical Sciences, Poznan, Poland; Biocontract, Poznan, Poland Correspondence to: Jacek Mackiewicz. Department of Medical and Experimental Oncology, Heliodor Święcicki Clinical Hospital, Poznań, Poland. Email: jmackiewicz@ump.edu.pl. Provenance: This is an invited article commissioned by the Editorial Office, Annals of Translational Medicine. Comment on: Eggermont AMM, Blank CU, Mandala M, et al. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/ KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. Eur J Cancer 2019;116:148-57.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research